SJEPD002_D.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 1.4
- e1_e2
- E2
- umap1_2d
- -6.237107589
- umap2_2d
- -0.911799732
- umap1_3d
- 1.300009537
- umap2_3d
- 3.100633183
- umap3_3d
- 0.247793422
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.300
- KRAS_SIGNALING_DN+0.280
- BILE_ACID_METABOLISM+0.190
- CHOLESTEROL_HOMEOSTASIS+0.150
- FATTY_ACID_METABOLISM+0.140
- XENOBIOTIC_METABOLISM+0.140
- ESTROGEN_RESPONSE_LATE+0.100
- PEROXISOME+0.100
- ADIPOGENESIS+0.070
- SPERMATOGENESIS+0.050
Top 10 suppressed
- PROTEIN_SECRETION-0.450
- TNFA_SIGNALING_VIA_NFKB-0.450
- ANDROGEN_RESPONSE-0.420
- INTERFERON_ALPHA_RESPONSE-0.380
- INTERFERON_GAMMA_RESPONSE-0.380
- INFLAMMATORY_RESPONSE-0.360
- MYC_TARGETS_V1-0.360
- APOPTOSIS-0.350
- G2M_CHECKPOINT-0.350
- ALLOGRAFT_REJECTION-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001520_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.931 |
| 2 | SJEPD001534_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.898 |
| 3 | SJEPD001522_R1.RNA-Seq | EPN | EPN Tumor | 0.891 |
| 4 | SJEPD007_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.891 |
| 5 | d2c9b21d-0f64-4182-9d5d-82b80a158a1f | — | — | 0.885 |
| 6 | TCGA-DK-A3IL-01A-11R-A20F-07 | — | — | 0.872 |
| 7 | SRR8613724 | — | F | 0.870 |
| 8 | SRR1333930 | GTEX | — | 0.867 |
| 9 | SRR1337564 | GTEX | — | 0.865 |
| 10 | SJEPD001530_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |